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Differential actions of angiotensin-(1-7) in the kidney. Angioten-
sin-(1-7) is a bioactive component of the renin-angiotensin system
that is endogenously formed in the circulation and various tissues
by several enzymatic pathways from either angiotensin (Ang) I or
Ang II. Initial studies indicated that Ang-(1-7) mimicked some of
the effects of Ang II, including stimulation of release of prosta-
noids and vasopressin. However, Ang-(1-7) is devoid of the
vasoconstrictor, central pressor, or thirst-stimulating actions asso-
ciated with Ang II. In fact, new findings reveal depressor, vasodi-
lator, and antihypertensive actions that may be more apparent in
hypertensive animals or humans. Thus, increasing evidence sug-
gests that Ang-(1-7) may oppose the actions of Ang II directly or
as a result of increasing prostaglandins or nitric oxide. In this
review, we examine recent studies to address whether the kidney
is a target organ for antihypertensive actions of Ang-(1-7).
It is well recognized that the renin-angiotensin system
plays an important role in renal function as part of the
system’s overall control of water and salt homeostasis. The
generation of angiotensin II (Ang II) from Ang I has long
been considered the final product of this biological cascade.
Ang II induces a variety of actions in the kidney including
potent vasoconstriction of the renal microcirculation, re-
lease of aldosterone to stimulate sodium reabsorption,
alteration of glomerular filtration, stimulation of sodium
and bicarbonate transport in the proximal tubules and the
promotion of mesangial cell hypertrophy [1].
Recent studies have revived the possibility that angioten-
sin peptides other than Ang II may either contribute to or
actually oppose the cardiovascular actions of Ang II, en-
dowing this hormonal system with a greater flexibility than
originally imagined. The characterization of Ang-(1-7) as
the first amino terminal angiotensin peptide product pos-
sessing biological actions provided a foundation for the
pursuit of a new concept regarding the regulation of
cardiovascular function by the renin-angiotensin system.
Indeed, the accumulating evidence suggests that Ang-(1-7)
may serve to counterbalance the actions of Ang II [2]. This
review updates the progress that has been made in the
development of this concept by examining the renal actions
of Ang-(1-7).
Tubular actions of Ang-(1-7)
Studies by Douglas and colleagues initially suggested
that Ang-(1-7) might have important actions on the kidney.
These authors found that Ang-(1-7) was more potent than
Ang II to inhibit transcellular sodium flux in cultured renal
tubular epithelial cells from rabbit [3]. The effects of
Ang-(1-7) were associated with an activation of phospho-
lipase A2. Moreover, they found that the inhibition of
sodium transport with Ang I was markedly potentiated by
the converting enzyme (ACE) inhibitor captopril. Proximal
tubules are an abundant source of the endopeptidase
neprilysin, which cleaves Ang I directly to Ang-(1-7) [4].
Thus, ACE inhibition may enhance Ang I to Ang-(1-7)
formation and attenuate the metabolism of Ang-(1-7) [5].
Consistent with the natriuretic actions of the peptide in
vitro, Ang-(1-7) infusion produced marked diuresis and
natriuresis in the isolated [6] and intact kidney of Sprague
Dawley (SD) and Wistar rats, respectively [7, 8]. In contrast
to the potent vasoconstriction produced by Ang II, Ang-
(1-7) lacked any effect on renal blood flow (RBF), nor did
Ang-(1-7) antagonize the actions of Ang II on RBF [6, 8].
In a subsequent report, the diuretic actions of Ang-(1-7) in
the isolated kidney were associated with increased prosta-
cyclin in the urinary and venous effluent; the cycloxygenase
inhibitor indomethacin attenuated the effects of the pep-
tide [9]. That Ang-(1-7) stimulates prostaglandin release
from the isolated kidney is consistent with the peptide’s
actions following chronic infusion in the spontaneously
hypertensive rat (SHR, and to a lesser extent in WKY
controls) [10] and various cell preparations [11]. In isolated
convoluted proximal tubules, low doses (10213 to 1029 M)
of Ang-(1-7) inhibited transport-dependent oxygen con-
sumption, a marker for Na1,K1-ATPase activity [8]. Inhi-
bition of this activity by Ang-(1-7) was partially blocked by
an AT1 antagonist and completely attenuated by the non-
selective antagonist [Sarcosine1,threonine8]-Ang II while
the AT2 antagonist PD 123319 had no effect [8]. However,
in a perfused preparation of straight proximal tubules,
Ang-(1-7) exhibited biphasic effects on water and bicarbon-
ate transport similar to that for Ang II [12]. Low concen-
trations (10212 M) of Ang-(1-7) stimulated water transport,
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while higher concentrations (1028 M) inhibited fluid ab-
sorption most probably by altering the affinity of the
Na1/H1 exchanger [12]. Both actions were completely
blocked by losartan, and partially by PD123319.
The tubular actions of Ang-(1-7) are either partially or
completely blocked by AT1 antagonists; however, the pep-
tide clearly lacks constrictive effects at renal or other
vascular AT1 receptor sites. These data suggest that Ang-
(1-7) may distinguish multiple AT1 receptor sites in the
kidney. Recent studies by Santos and colleagues also
indicate that Ang-(1-7) interacts with a novel AT1 or
losartan-sensitive site in the kidney [14–16]. In water-
loaded Wistar rats, Ang-(1-7) promotes an anti-diuretic
action with a tendency for increased plasma vasopressin
[13]. The anti-diuretic effects were attenuated by the AT1
agent losartan and the Ang-(1-7) antagonist D-[Ala7]-Ang-
(1-7) [14]. Santos et al [15] have also reported that the
peptide inhibits water transport in a collecting duct prepa-
ration, an effect blocked by the D-[Ala] antagonist. The
D-[Ala]-Ang-(1-7) compound does not inhibit Ang II bind-
ing at either the AT1 or AT2 sites in the adrenal, nor
attenuates the vasoconstrictor effects of Ang II [16].
The anti-diuretic effects of Ang-(1-7) are in direct con-
trast to the effects observed in the isolated and in situ
perfused kidney, or with chronic infusion in SHRs. One
obvious difference in the studies with intact animals was
that the experiments were performed after water loading.
Burnier et al [17] reported conflicting results concerning
AT1 treatment of patients following an acute water load.
These findings emphasize that the overall state of sodium
and water balance (and perhaps the overall activity of the
renin-angiotensin system) may be critically important in
determining the effects of Ang-(1-7) in the kidney. More-
over, the route of administration, the site of the nephron
exposed to Ang-(1-7), and the dose of the peptide may
influence the direction of observed actions.
Ang-(1-7) may access the kidney through the circulation
or by intra-renal generation. The biochemical components
to yield Ang-(1-7) including renin, angiotensinogen, Ang I
and neprilysin are present within the kidney, particularly
within the proximal tubules. A potential insight into the
role of Ang-(1-7) in renal function was gained by the
demonstration of the heptapeptide in rat urine. As shown
in Figure 1A, we compared the concentration of angioten-
sin peptides from renal tissue [18] and urine [19] in SD rats.
In contrast to tissue, urinary levels of immunoreactive
Ang-(1-7) are higher than those of Ang II, but comparable
to Ang I. Analysis of urine extracts by high performance
liquid chromatography (HPLC) revealed a predominant
immunoreactive peak that corresponds to the Ang-(1-7)
standard, with a smaller peak at a retention time corre-
sponding to Ang-(3-7) (Fig. 1B). To determine whether
urinary Ang-(1-7) results from the proteolysis of Ang I in
urine, we assessed the metabolism of 125I-labeled Ang I, in
pooled urine samples. HPLC analysis of 125I-Ang I metab-
olism following a 30 minute incubation did not reveal the
presence of either labeled Ang II or Ang-(1-7); only smaller
peptide fragments were detected (Fig. 1C). Inhibition of
Ang I metabolism by the chelating agents EDTA and
O-phenanthroline (OP) did not reveal the presence of
Ang-(1-7) or Ang II, which suggests that excretion of
Ang-(1-7) does not arise from the conversion of Ang I or
Ang II to Ang-(1-7) by urinary peptidases, but from either
tissue release of the peptide or the luminal processing of a
precursor such as Ang I or Ang II. We have begun to
address whether the excretion of Ang-(1-7) is under dy-
namic control or is constituitively secreted. A five-day
treatment with lisinopril significantly increased the urinary
excretion of both Ang I and Ang-(1-7) in SD rats (Fig. 2A).
Since we have shown that Ang-(1-7) is degraded by ACE,
this effect may result from protection of Ang-(1-7) [5]. We
and others have shown that plasma levels of Ang-(1-7) are
markedly elevated following chronic treatment with ACE
inhibitors [20–22]. Although it is presently unknown
Fig. 1. Renal excretion of Ang-(1-7). (A) Comparison of renal tissue [18]
and urinary excretion [19] of angiotensin peptides in Sprague Dawley (SD)
rats. Symbols are: (f) Ang I; (M) Ang-(1-7); (p) Ang II. (B) HPLC
analysis of immunoreactive angiotensin-(1-7) [Ang-(1-7)] in urinary ex-
tract from a SD rat. Arrows indicate the elution times of Ang-(1-7)
standards. (C) Chromatographic analysis of 125I-Ang-I metabolism in rat
urine. 125I-Ang I (0.5 nM) was incubated with rat urine for 30 minutes at
37°C in the presence (dashed line) or absence (solid line) of EDTA/
phenanthroline (OP; 1 mM each) and subjected to HPLC analysis as
described [26].
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whether the increased urinary excretion of Ang-(1-7) con-
tributes to the renal actions of ACE inhibitors, we have
recently shown that Ang-(1-7) contributes to the antihyper-
tensive effects of combined lisinopril/losartan in the SHR
[23, 24]. In addition, the combined treatment with lisinopril
and the orally active NEP inhibitor CGS 25460 lowered
excretion of Ang-(1-7) to control levels, but further aug-
mented Ang I and increased Ang II (Fig. 2A).
Ang-(1-7) has been characterized in the urine from
human subjects as well [25]. As shown in the bottom panel
of Figure 2, untreated essential hypertensive subjects ex-
hibited a lower urinary excretion rate of Ang-(1-7) than
normotensive controls [12.2 6 1.7 pmol Ang-(1-7) nmol
creatinine21 (Cr) 24 hours21 versus 5.78 6 0.92 pmol
Ang-(1-7) nmol Cr21 24 hours21, respectively (P , 0.007]).
Furthermore, urinary concentrations of Ang-(1-7) corre-
lated inversely with arterial pressures (r 5 20.48, P ,
0.001), while both urinary Ang-(1-7) (odds ratio 0.92; 95%
CI, 0.88 to 0.97) and age were independent predictors of
systolic blood pressure. The inverse association between
Ang-(1-7) and arterial pressure may provide a potential
marker for the characterization of forms of essential hyper-
tension associated with reduced production or activity of
diuretic/natriuretic hormones.
SUMMARY
Studies of the effects Ang-(1-7) in the kidney suggest that
the renin-angiotensin system possesses the ability to either
limit or possibly promote sodium and water excretion
through the alternative processing of Ang I. Further studies
are necessary to clearly establish the role of Ang-(1-7) in
physiologic and pathophysiologic conditions. In this regard,
the use of more selective agents to delineate the actions of
Ang-(1-7) from those of Ang II will be critically important
to resolve the renal actions of Ang-(1-7).
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